An observational study in Lung Transplant, sponsored by XVIVO Perfusion. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by XVIVO Perfusion · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The XVIVO Registry is to collect standard of care clinical data from "all-comers" who are transplanted with an EVLP lung treated with the XVIVO Perfusion System™ in order to assess the long-term performance of the device, and monitor device-related serious adverse events. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data.
The XVIVO registry is an ongoing, observational, multicenter, retrospective review of patients exposed to XPS™ EVLP-treated lungs. The Registry study is aligned and managed by the UNOS and OPTN data collection process. This registry uses quarterly STAR file data requests for the OPTN data managed by UNOS.
The EVLP procedure and transplantation will be performed per XPS™ Instructions for Use and the treating physician's discretion. Post-transplant clinical care will follow the institution's standard-of-care policies.
OPTN updated the data collected since the submission of the protocol therefore the data collection has changed. The following data has updated collection:
XVIVO Perfusion is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is an "All Comers Registry" hence, no specific investigator sites. All patients receiving EVLP lungs treated with XPS™ will be included in the registry without eligibility criteria or pre-selection. Since the registry collects only standard-of-care data and requires no additional procedures or risks to the subject, a waiver of consent is appropriate
This is an "All Comers Registry" hence will include all patients receiving EVLP lungs.
XVIVO Perfusion System (XPS™) with STEEN Solution™
Survival at 1 year post-transplant
Primary effectiveness endpoint
Time frame: 12 months
Primary Graft Dysfunction (PGD)
Rate of Grade 3 Primary Graft Dysfunction (PGD) at 72 hours
Time frame: 72 hours
Post-transplant survival
Survival at 2, 3, 4 and 5 years post-transplant
Time frame: 2 years, 3 years, 4 years and 5 years post-transplant
Pulmonary Function Test (FEV1)
Pulmonary Function Test (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 is the key lung function test in diagnosing BOS. FEV1 test at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant.
Time frame: 1 year, 2 years, 3 years, 4 years and 5 years post-transplant
Incidence of Bronchiolitis Obliterans Syndrome (BOS) or Chronic Lung Allograft Dysfunction (CLAD)
Rate of Grade 0 through 3 Bronchiolitis Obliterans Syndrome (BOS) at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant. Clinically, BOS is associated with a progressive decline in forced expiratory volume in one second (FEV1) greater than or equal to 20% of baseline. Decline in FEV1 % increases the risk of development of BOS (Grade 0 to 3). CLAD is defined as a substantial and persistent decline (≥ 20%) in measured FEV1 value from the reference (baseline) value after lung transplantation, with or without a change in FVC. If CLAD is identified, staging and phenotype will be assigned.
Time frame: 1 year, 2 years, 3 years, 4 years and 5 years post-transplant
Hospitalizations
The presence of in-patient hospital admissions between transplant and 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant
Time frame: 1 year, 2 years, 3 years, 4 years and 5 years post-transplant
Acute Rejection Episodes
The presence of biopsy proven hospital admissions between transplant and 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant
Time frame: 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant
Karnofsky Performance Status Scale (KPS)/Karnofsky score
Karnofsky Performance Status Scale is an assessment tool for functional impairment. It is used to improve understanding of patient needs, ability to carry out daily activities and to assess patient prognosis. Karnofsky score is calculated at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant. Higher the Karnofsky score, better the ability to carry out daily activities.
Time frame: 1 year, 2 years, 3 years, 4 years and 5 years post-transplant
Safety Endpoint
XPS related SAEs from transplant to 30 days post-transplant or initial hospital stay, whichever is longer
Time frame: 30 days post-transplant
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2019 (actual). Primary completion is estimated for Apr 2029, 113 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
XVIVO Perfusion